Control of innate immune system for cancer therapy;Mobiliser l'immunité innée dans le traitement des cancers

Medecine/Sciences

Volumn 29, Issue 11, 2013, Pages 985-990

  Garaude, Johan ^a,b  

^a Centre national d'investigations cardiovasculaires   (Spain)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; IMMUNOGLOBULIN RECEPTOR; INFLAMMASOME; TOLL LIKE RECEPTOR;

HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; NEOPLASM; REVIEW;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; INFLAMMASOMES; INFLAMMATION; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTORS;

EID: 84889664974     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20132911014     Document Type: Review

References (34)

1. Iwasaki, A; Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 2010; 327: 291-295.
2. Mellman, I; Coukos, G; Dranoff, G. Cancer immunotherapy comes of age. Nature 2011; 480: 480-489.
3. Kanzler, H; Barrat, FJ; Hessel, EM; Coffman, RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-559. (Pubitemid 46830615)
4. Grivennikov, SI; Greten, FR; Karin, M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
5. Chalmin, F; Mignot, G; Ghiringhelli, F. Cellules myéloïdes suppressives et cancer: une nouvelle cible thérapeutique. Med Sci (Paris) 2010; 26: 576-579.
6. Finn, OJ. Cancer immunology. N Engl J Med 2008; 358: 2704-2715.
7. Guha, M. Anticancer TLR agonists on the ropes. Nat Rev Drug Discov 2012; 11: 503-505.
8. Galluzzi, L; Vacchelli, E; Eggermont, A; et al. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1: 699-716.
9. Heldwein, KA; Liang, MD; Andresen, TK; et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol 2003; 74: 277-286. (Pubitemid 38040425)
10. Cheever, MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222: 357-368. (Pubitemid 351430366)
11. Zitvogel, L; Kepp, O; Galluzzi, L; Kroemer, G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13: 343-351.
12. Hu, B; Elinav, E; Huber, S; et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA 2010; 107: 21635-21640.
13. Normand, S; Delanoye-Crespin, A; Bressenot, A; et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci USA 2011; 108: 9601-9606.
14. Allen, IC; TeKippe, EM; Woodford, RM; et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207: 1045-1056.
15. Goutagny, N; Estornes, Y; Hasan, U; et al. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol 2012; 7: 29-54.
16. Kasturi, SP; Skountzou, I; Albrecht, RA; et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470: 543-547.
17. Trinchieri, G; Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7: 179-190.
18. Rathinam, VA; Vanaja, SK; Waggoner, L; et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 2012; 150: 606-619.
19. Apetoh, L; Ghiringhelli, F; Tesniere, A; et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059. (Pubitemid 47517504)
20. Ghiringhelli, F; Apetoh, L; Tesniere, A; et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
21. Bruchard, M; Mignot, G; Derangere, V; et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19: 57-64.
22. Steinman, RM; Banchereau, J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426. (Pubitemid 47509552)
23. Zhang, X; Majlessi, L; Deriaud, E; et al. Coactivation of Syk kinase and MyD88 adaptor protein pathways by bacteria promotes regulatory properties of neutrophils. Immunity 2009; 31: 761-771.
24. Blander, JM; Medzhitov, R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440: 808-812.
25. Schulz, O; Diebold, SS; Chen, M; et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433: 887-892. (Pubitemid 40314900)
26. Forbes, NS. Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer 2010; 10: 785-794.
27. Skoberne, M; Yewdall, A; Bahjat, K; et al. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity. J Clin Invest 2008; 118: 3990-4001.
28. Smith, KD; Andersen-Nissen, E; Hayashi, F; et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003; 4: 1247-1253. (Pubitemid 37540694)
29. Kofoed, EM; Vance, RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011; 477: 592-595.
30. Garaude, J; Kent, A; van Rooijen, N; Blander, JM. Simultaneous targeting of toll-and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012; 4: 120ra-116.
31. Jamilloux, Y; Henry, T. Les inflammasomes: plates-formes de l-immunité innée. Med Sci (Paris) 2013; 29: 975-984.
32. Tartour, E; Sandoval, F; Bennefoy, JY; Fridman, WH. Immunothérapie des cancers. Med Sci (Paris) 2011; 27: 833-841.
33. Jobin, C. Microbiome: un nouveau facteur de risque de cancer colorectal ? Med Sci (Paris) 2013; 29: 582-585.
34. Apetoh, L; Ghiringhelli, F; Zitvogel. La calréticuline détermine l-immunogénicité de la chimiothérapie et de la radiothérapie anti-tumorales. Med Sci (Paris) 2007; 23: 257-258.